Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Exposure to arsenic in drinking water may interact with common genetic variants in urinary bladder cancer risk.
Methods: We conducted a gene-environment interaction analysis among 1091 bladder cancer cases and 928 controls from the New England Bladder Cancer Study. Genetic variants tested as effect modifiers included those associated with bladder cancer and arsenic metabolism. Interactions with disease-specific polygenic scores and a genome-wide gene-environment interaction analysis were also conducted. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated with average arsenic concentration (µg/L), average daily arsenic (µg/day), and cumulative arsenic (mg) in water as exposures.
Results: Multiplicative interactions for bladder cancer risk were identified for cumulative arsenic and rs1046428 of GSTZ1 on 14q23 (TT and TC genotype: ORT3vsT1 = 1.44, 95% CI = 1.05 to 1.98; Pinteraction = .01) and for average daily arsenic and rs1801133 (C677T) and rs1801131 (A1298C) of MTHFR on 1p36 (TT and TC genotypes: ORT3vsT1 = 1.53, 95% CI = 1.06 to 2.23; Pinteraction = .02; CC and CA genotype: ORT3vsT1 = 1.63, 95% CI = 1.16 to 2.29; Pinteraction =.01, respectively). A global interaction between arsenic exposure and polygenic scores was also observed (ORT3vsT1 = 1.80, 95% CI = 1.26 to 2.56; Pinteraction =. 01). Genome-wide gene-environment interaction analyses suggested interactions with 5 loci with a Pinteraction of no more than 5e-6.
Conclusions: Genetic variants that function in arsenic metabolism involving folate and oxidative stress pathways and a global summary of genetic susceptibility to bladder cancer may modify the association between elevated arsenic exposure from drinking water and bladder cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249215 | PMC |
| http://dx.doi.org/10.1093/jncics/pkaf064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MAP30 inhibits proliferation and metastasis of bladder cancer by increasing EGR1 expression and promoting the transcriptional activation of DUSP1.
Mol Immunol
September 2025
Department of Surgical Urology, the Third Affiliated Hospital of Soochow University, No. 185, Jiuqian Street, Changzhou, Jiangsu 213003, China. Electronic address:
The confirmed tumor-inhibitory effects of the 30 kDa Momordica anti-human immunodeficiency virus protein (MAP30) have yet to be complemented by an exploration into its mechanism of action on tumor development and metastasis. For this purpose, we delved into the intrinsic mechanism of MAP30 in bladder cancer (BC). Here, we demonstrated that MAP30 markedly suppressed the proliferation, migration, invasion, and angiogenic capabilities of human BC cells in vitro, and the tumor metastatic potential in vivo.
View Article and Find Full Text PDFPurpose: To describe our integrated pelvic fascial structure-sparing (IPFSS) technique for robotic-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder (ONB) reconstruction and to evaluate its impact on urinary continence and sexual function in male patients.
Methods: This retrospective observational study was conducted at a single high-volume center. Male bladder cancer patients who underwent IPFSS RARC with ONB were included.
AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in Bladder Cancer via Multi-parametric Imaging: A Systematic Review and Meta-analysis.
Acad Radiol
September 2025
Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China (H.S., Q.W., S.F., H.W.). Electronic address:
Rationale And Objectives: This study systematically evaluates the diagnostic performance of artificial intelligence (AI)-driven and conventional radiomics models in detecting muscle-invasive bladder cancer (MIBC) through meta-analytical approaches. Furthermore, it investigates their potential synergistic value with the Vesical Imaging-Reporting and Data System (VI-RADS) and assesses clinical translation prospects.
Methods: This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Urinary organs-at-risk for radiotherapy following radical prostatectomy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU).
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.
View Article and Find Full Text PDF